01:55 PM EDT, 07/24/2024 (MT Newswires) -- Sophia Genetics ( SOPH ) said Wednesday that OncoHelix, a research and precision diagnostics laboratory in Canada, will implement liquid biopsy MSK-Access powered with Sophia DDM beginning this summer.

MSK-Access with SOPHiA DDM is a decentralized ctDNA test developed by Memorial Sloan Kettering Cancer Center, according to the company.

Sophia said that OncoHelix is the first laboratory in Canada to use the liquid biopsy, which will go live later this summer.

Financial terms of the collaboration were not disclosed.

Price: 4.68, Change: +0.06, Percent Change: +1.41